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Copenhagen, Denmark
Background: Airway responsiveness and inflammation are associated with the clinical mani-
festations of asthma and the response to pharmacological therapy.
Objective: To investigate if airway responsiveness and inflammatory characteristics are related 
to asthma exacerbations during pregnancy.
Materials and methods: In women with asthma who were prescribed controller medication 
and monitored closely during pregnancy, the risk of exacerbations was analyzed in relation to 
postpartum measures of fractional exhaled nitric oxide (F
E
NO), skin prick test reactivity, static 
and dynamic lung volumes, diffusing capacity for carbon monoxide, bronchial responsiveness 
to inhaled mannitol, and inflammatory characteristics in induced sputum. Obtained data were 
analyzed in relation to exacerbation status during pregnancy. The PD
15
 is defined as the cumulative 
administered dose causing a 15% decline in forced expiratory volume in the first second (FEV
1
).
Results: Fifty women (mean age ± standard deviation of 32±5 years) were enrolled over an 
11-month period and examined on average 4 months postpartum. During pregnancy, 13 women 
had a total of 16 exacerbations (8 mild and 8 severe). Women with asthma exacerbation during 
pregnancy had more pronounced airway responsiveness to inhaled mannitol (geometric mean PD
15
 
82 vs 171 mg, p=0.04) and were less likely to be atopic (62% vs 86%, respectively; p=0.04) than the 
non-exacerbators. No statistically significant difference was found between the 2 groups of women 
with regard to type of airway inflammation in sputum and fractional exhaled nitric oxide (F
E
NO).
Conclusion: More pronounced airway hyperresponsiveness together with nonatopic status 
appears to characterize women at high risk of exacerbation of asthma during pregnancy.
Keywords: asthma, inflammation, pregnancy
Introduction
Asthma is characterized by variable airflow obstruction, airway hyperresponsiveness, 
and airway inflammation.1 Airway inflammation is a major factor determining the 
degree of airway responsiveness2 and may predict both the course of asthma and the 
response to anti-asthma therapy.3,4 Furthermore, it is generally accepted, also in inter-
national guidelines, that treating airway inflammation is a prerequisite for achieving 
sufficient symptom control in asthma.5
The prevalence of asthma is higher in women than in men.6,7 One-third of pregnant 
women with asthma will experience a worsening in their asthma,8 and an exacerbation 
of asthma during pregnancy is the most significant risk factor for fetal morbidity and 
mortality in asthmatic mothers.9 Despite abundant evidence of the occurrence of asthma 
exacerbations during pregnancy8 and its adverse effect on pregnancy outcomes,10,11 
our knowledge of the mechanisms underlying an exacerbation remains limited, largely 
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because investigations have been restricted to retrospective- 
and register-based studies. Furthermore, studies so far have 
primarily looked at asthma severity,9,12 smoking,13 adherence 
with asthma medication,14 and obesity15 as risk factors for 
exacerbations of asthma during pregnancy, whereas studies 
have not evaluated airway responsiveness, except the study 
by Juniper et al,16 or airway inflammation in pregnant women 
with asthma, either during pregnancy or postpartum. A pro-
spective study by Juniper et al16 with 16 participants found 
no changes in airway hyperresponsiveness to methacholine 
inhalation test 1 month postpartum compared to preconcep-
tion mean.
The aim of the present pilot study was to investigate 
potential differences in physiological and inflammatory 
characteristics between women with and without asthma 
exacerbation during pregnancy.
Materials and methods
Materials
Pregnant women with asthma referred to give birth at Hvi-
dovre Hospital have since 2007 been offered participation 
in the Management of Asthma during Pregnancy (MAP) 
program at the outpatient clinic at the Department of Pul-
monary Medicine, Hvidovre Hospital. Scheduled follow-up 
visits were planned every 4 weeks during pregnancy with 
adjustment, if necessary, of asthma medication based on 
symptoms, level of fractional exhaled nitric oxide (F
E
NO), 
and spirometry in accordance with the algorithm subse-
quently described by Powell et al.17 The MAP study has been 
described in detail previously.18–21
Inclusion criteria for the present study were:
1. Enrolled in the MAP program during 2015.
2. Prescribed controller medication, ie,  inhaled 
corticosteroid.
3. Delivery within the past 9 months.
One hundred and four women fulfilled the inclusion criteria 
and were invited consecutively from November 2015 to 
September 2016 to a postpartum examination.
Definitions
Smoking status was classified as current smokers, ex-
smokers, or lifelong non-smokers. Pack-years (number of 
cigarettes per day/20× duration of smoking [years]) were 
used as an estimate of life-time tobacco exposure. Exposure 
to environmental tobacco smoke (ETS) was defined as living 
with someone smoking at home (as smoking in work places, 
restaurants etc. is currently not allowed in Denmark).
Self-reported adherence with controller medication was 
recorded (at each visit to the out-patient clinic) as good, 
acceptable, or poor.
Exacerbations were defined as mild (managed by an 
increase in therapy, but not requiring oral corticosteroids) or 
severe (requiring hospital admission, emergency department 
treatment, and/or a rescue course of systemic corticosteroids).
Methods
The postpartum examination program included the following 
procedures: measurement of F
E
NO, skin prick test (SPT), 
body plethysmography, spirometry, diffusing capacity for 
carbon monoxide (DLCO), bronchial provocation test with 
mannitol, and induction of sputum.
Exhaled nitric oxide
F
E
NO was measured with Eco Medics CLD 88sp analyzer 
and DENOX 88 (Eco Medics, Duernten, Switzerland) at 
a controlled flow rate of 50 mL/s according to American 
Thoracic Society (ATS) guidelines.22 The mean value of 2 
measurements in parts per billion (ppb) was recorded.
SPT
The SPT was performed according to European Academy of 
Allergy and Clinical immunology standards23,24 and a wheal 
diameter ≥3 mm was defined positive. SPT was performed 
with a panel of aeroallergen extracts, including birch (Betula 
verrucosa), grass (Phleum pratense), mugworts (Artemisia 
vulgaris and Ambrosia artemisiifolia), cat (Felix domesticus), 
dog (Canis familiaris), horse (Equus caballus), house dust 
mite (Dermatophagoides pteronyssinus and Dermatophagoi-
des farinae), and molds (Alternaria alternata, Cladosporium 
herbarum, and Aspergillus fumigatus). Positive (10 mg/mL 
histamine hydrochloride solution) and negative (diluent) 
controls were used. Subjects were considered atopic if they 
had a positive reaction to at least one of the aeroallergens.
Spirometry, plethysmography, and diffusing capacity
Forced expiratory volume in the first second (FEV
1
) from 
a maximum inspiration, forced vital capacity (FVC), along 
with vital capacity (VC), residual volume (RV), total lung 
capacity (TLC), forced residual capacity, specific airway 
conductance, and functional residual capacity (FRC) were 
measured using a whole body plethysmograph25 and were 
performed according to the ATS/European Respiratory 
Society guidelines26 using standardized equipment (Jaeger 
MasterScreen Body; IntraMedic, Sollentuna, Sweden). 
Prior to each test calibration was conducted according to the 
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manufacturer’s instructions. The procedure was explained in 
detail, and the maneuver was demonstrated to the patient.
DLCO was measured by the single-breath carbon mon-
oxide (CO) gas transfer method, and the predicted DLCO 
was adjusted for hemoglobin.27 The patient inhaled a gas 
mixture containing 0.3% CO, 9.3% helium, 21% oxygen, and 
nitrogen to make up the balance. All results are expressed as 
percentage predicted.
Mannitol bronchial provocation test
The mannitol bronchial provocation test was performed 
using the commercial mannitol kit Osmohale© Pharmaxis 
(Pharmaxis Ltd, Sydney, NSW, Australia) according to the 
method described by Anderson et al.28 The mannitol capsule 
dose started at 0 mg (placebo) and increased (5, 10, 20, 40, 
80, 160, 160, and 160 mg) to a total cumulative dose of 
635 mg of mannitol. A positive response was defined as a fall 
in FEV
1
 ≥15% with a cumulative dose of mannitol ≤635 mg 
(PD
15
). The PD
15
 was calculated by linear interpolation of the 
individual dose–response relationship between the percent-
age decrease in FEV
1
 and the cumulative dose of mannitol 
required to provoke this decrease. Rescue bronchodilator was 
administered at the end of the challenge test to aid recovery.
Induced sputum
Hypertonic (3.5%) saline was nebulized with an ultrasonic neb-
ulizer (Ultrasonic inhalation device USC, [Medisana, Neuss, 
Germany]) with an output of ~1 mL/min at room temperature. 
The induction was performed at 5-min intervals for ≤15 min. 
The women were instructed to cough and spit after 5, 10, and 
15 min of induction or whenever they got the urge to do so.
Sputum plugs were selected from the expectorate and 
analyzed according to the method described by Pizzichini 
et al.29 Cytospins were prepared and stained with May-
Grünwald and Giemsa stain, and differential cell count of 
400 non-squamous cells was performed.
Squamous cells were counted to determine sample qual-
ity. A sputum sample of inadequate quality was defined as a 
squamous cell percentage of >80%.30
Sputum samples were categorized into 4 subgroups 
based on the prevailing sputum cell count: eosinophilic 
(>3% eosinophils), neutrophilic (>60% neutrophils), mixed 
granulocytic (>3% eosinophils and >60% neutrophils), and 
paucigranulocytic (<3% eosinophils and <60% neutrophils).31
Outcome
The primary outcome variable was airway responsiveness 
to mannitol (PD
15
) at the postpartum examination in women 
with and without asthma exacerbation during pregnancy.
The secondary outcome variables were:
1. eosinophilic inflammation vs neutrophilic inflammation 
in induced sputum,
2. SPT reactivity,
3. F
E
NO level (ppb),
4. FEV
1
% of predicted, and
5. static lung volumes and diffusion capacity.
Statistical analysis
Data were analyzed using SAS Enterprise Guide 7.1. Con-
tinuous data were analyzed by the 2-sample t-test and binary 
outcomes by the Chi square test or Fisher’s exact test. Geo-
metric mean was given for PD
15
 along with 95% confidence 
interval (CI). Mann–Whitney test was used to analyze the 
association between asthma exacerbations and PD
15
 because 
the PD
15
 data were not normally distributed. For each associa-
tion a crude model was first analyzed and then adjusted for 
potential confounders: age, smoking status (never smoker vs 
ever smoker), inhaled corticosteroids (ICS) treatment (low 
dose vs middle and high dose), and self-reported adherence 
with ICS (good/acceptable vs poor).
The response–dose ratio (RDR) was calculated according 
to the method described by O’Connor et al,32 as the percent-
age decline in FEV
1
 after the last mannitol dose divided by 
the cumulative mannitol dose in milligrams. To meet normal 
distribution, log-transformed values of RDR were used, and 
an additional 1% was added to the percentage decrease in 
FEV
1
 to
 
eliminate zero values.32 The relationship between 
airway responsiveness to mannitol expressed as the RDR 
and the airway inflammation in sputum was analyzed using 
Pearson’s correlation coefficient (r), with -1 indicating a 
perfect negative correlation, +1 indicating a perfect positive 
correlation, and 0 indicating no correlation at all.
A p-value ≤ 0.05 was considered significant.
Ethics statement
This study was performed in accordance with the Declara-
tion of Helsinki II and according to Danish legislation. The 
study was approved by the Research Ethics Committee of 
the Capital Region of Denmark (H-2-2014-051) and by the 
Danish data protection agency (2007-58-0015). All patients 
provided written informed consent.
Results
During the 11-month study period, 104 women fulfilled the 
inclusion criteria, of whom 50 (48%) women accepted the 
invitation and were examined 1–7 months after delivery. In 
13 women, a total of 16 exacerbations (8 mild and 8 severe) 
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were observed during pregnancy. The general characteristics 
of the participants are presented in Table 1.
The result of the SPT had to be omitted in 1 patient due 
to a reaction to the negative control.
The mannitol test was positive in 78% (n=39) with a geo-
metric mean PD
15
 of 137 mg (95% CI 99–189). There were 
no significant differences between women with a positive 
and a negative mannitol provocation test with regard to age, 
lung function parameters, smoking status, allergy, and F
E
NO.
Sputum induction was successful in 40 out of 50 women 
(success rate 80%). The cell viability in the sputum samples 
was 89.9±7.9%, and the median squamous cell contamina-
tion was 0.3±0.8 (range 0–4%). There were no significant 
differences between patients with and without successful 
induction of sputum according to age, lung function param-
eters, smoking status, and allergy. However, women with 
successful sputum induction had significantly higher level of 
F
E
NO compared to those with unsuccessful sputum induction 
(mean F
E
NO level 21 ppb and 12 ppb, respectively, p=0.04).
No significant difference was found in prevalence of 
airway responsiveness to mannitol between women with and 
without an asthma exacerbation during pregnancy, however, 
women with an exacerbation were more responsive than 
women without an exacerbation (geometric mean PD
15
 82 vs 
178 mg, p=0.04). Furthermore, there was a significant posi-
tive correlation between the degree of airway responsiveness 
to mannitol (RDR mannitol) and neutrophil count in sputum 
(r=0.44, p=0.01) (Figure 1), but not to the eosinophil count 
(r=0.00, p=0.97).
Women without an asthma exacerbation during pregnancy 
were more likely to have a positive SPT compared to women 
with exacerbation (86% vs 62%, odds ratio [OR] 0.20, 95% 
CI 0.05–0.92, p=0.04) (Table 2).
There were no significant changes in lung function 
parameters, the level of F
E
NO, and inflammatory phenotypes 
after adjusting for age, smoking status, ICS treatment, and 
self-reported adherence with ICS.
There were no significant differences in women with 
and without an exacerbation during pregnancy regarding 
the inflammatory phenotype in sputum, ie, eosinophilia or 
neutrophilia.
Discussion
In the present study of pregnant women with asthma, we 
found that women with an exacerbation during pregnancy 
were more responsive to inhaled mannitol and more likely 
to be nonatopic compared to women without asthma 
exacerbations.
Our results are in line with Leuppi et al,33 who have 
reported that increased responsiveness to mannitol is a bet-
ter indicator for loss of asthma control than symptoms, spi-
rometry, and/or F
E
NO. Furthermore, we found that the level 
of airway responsiveness to mannitol was associated with 
sputum neutrophilia, which supports findings from another 
study by Leuppi et al.34 The lack of an association between 
sputum eosinophilia and airway responsiveness in our popu-
lation is similar to the results in a study of Simpson et al.31 
In contrast, Porsbjerg et al35 have observed a higher level of 
airway responsiveness to mannitol in eosinophilic asthma, 
which may be explained by the difference in the population. 
In the study by Porsbjerg et al,35 the cohort of patients studied 
were not on controller therapy, ie, ICS, whereas all the women 
in our cohort were treated with ICS. Eosinophilia in sputum 
is effectively reduced by ICS treatment,36 while neutrophilic 
inflammation in sputum shows little or no response to ICS.36 It 
is likely that treatment with ICS has reduced the eosinophilic 
Table 1 Characteristics of women (n=50) followed throughout 
pregnancy in the Management of Asthma during Pregnancy 
program with postpartum assessment of asthma status
Characteristics Women (n=50)
Time since birth (days) 124±39 (33–207)
Age (years) 32±5 (22–42)
Body mass index (kg/m2) 26±5 (19–37) 
Rhinitis 40 (80)
Nulliparous 16 (32)
Male child 24 (48)
Exacerbation of asthma during pregnancy
Total exacerbations 13 (26)
Mild exacerbations 8 (16)
Severe exacerbations 8 (16)
Asthma controller therapy
Daily dose of inhaled corticosteroid (n=50)a
Low 36 (72)
Middle 11 (22)
High 3 (6)
Second controller therapy
Long-acting β2-agonist 21 (42)
Leukotriene receptor antagonist 1 (2)
Smoking status
Current-smoker 1 (2)
Pack-years 14
Ex-smoker 9 (18)
Pack-years 7± 4 (2–15)
Never-smoker 40 (80)
Environmental tobacco exposure 5 (10)
Self-reported adherence
Good/acceptable 39 (78)
Notes: Data are given as mean ± SD with range in brackets or numbers with 
percentages in brackets. aGiven in beclomethasone dipropionate equivalent doses.
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Figure 1 Neutrophil count in induced sputum vs airway responsiveness to inhaled mannitol, expressed as the RDR, in a postpartum evaluation of 50 women with asthma 
followed throughout pregnancy in the Management of Asthma during Pregnancy program.
Note: RDR, the percentage decline in FEV1 after the last mannitol dose divided by the cumulative mannitol dose in milligrams.
Abbreviations: FEV1, forced expiratory volume in the first second; RDR, response–dose ratio.
Log RDR mannitol
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Table 2 Univariate analyses of 50 women (31 without and 13 with asthma exacerbation) followed throughout pregnancy in the 
Management of Asthma during Pregnancy program with postpartum asthma evaluation
Variables No exacerbation, 
n=37
Exacerbation,  
n=13
ORcrude (95% CI) ORadj (95% CI) p-valueadj
Atopic 32 (86) 8 (62) 0.20 (0.44–0.92) 0.11 (0.02–0.69) 0.02
Exhaled nitric oxide
FENO
a (ppb) 18±12 20±13 1.02 (0.97–1.07) 1.01 (0.96–1.08) NS
FENO > 25 ppb 10 (27) 4 (31) 1.20 (0.30–4.79) 1.13 (0.24–5.30) NS
Lung function parameters
FEV1% predicted 100.6±18.5 93.1±19.7 0.98 (0.94–1.01) 0.98 (0.94–1.02) NS
FEV1<80% predicted 4 (11) 4 (31) 3.67 (0.76–17.62) 4.24 (0.7822.97) NS
FEV1/FVC ratio (%) 77.3±6.0 76.4±7.9 0.98 (0.89–1.08) 0.99 (0.89–1.10) NS
FEV1/FVC < LLN
b 6 (16) 4 (31) 2.30 (0.53–9.95) 2.19 (0.49–9.69) NS
Total lung capacity % predicted 113.3±23.3 110.9±10.0 0.99 (0.96–1.03) 1.00 (0.96–1.03) NS
Residual volume % predicted 111.6±18.9 126.2±37.2 1.02 (0.98–1.05) 1.02 (0.98–1.05) NS
Vital capacity % predicted 113.7±32.0 103.3±14.1 0.98 (0.94–1.02) 0.97 (0.93–1.02) NS
Functional residual capacity % predicted 109.5±19.9 113.1±19.5 1.01 (0.98–1.04) 1.01 (0.98–1.05) NS
Specific airway conductance % predicted 100.7±25.8 107.5±58.1 1.01 (0.99–1.02) 1.01 (0.99–1.02) NS
Diffusing capacity % predictedc 74.8±8.8 74.4±6.7 0.99 (0.92–1.07) 0.98 (0.89–1.07) NS
Mannitol challenge test
Positive test 27 (73) 12 (92) 3.86 (0.44–33.91) 4.65 (0.49–43.88) NS
Geometric mean of mannitol PD15 (mg) 171 (118–246) 82 (44–156) 0.99 (0.98–0.99) 0.99 (0.98–0.99) 0.05
Inflammatory phenotype
Eosinophilic 9 (24) 2 (15) 0.30 (0.03–2.52) 0.30 (0.02–4.80) NS
Neutrophilic 4 (11) 3 (5) 3.38 (0.40–28.74) 3.31 (0.21–52.48) NS
Mixed granulocytic 0 (0) 2 (15) – – NS
Paucigranulocytic 16 (43) 4 (31) – – NS
Notes: Data are given as mean ± SD or numbers with row percentages in parentheses. The cumulative dose of mannitol causing a 15% decline in FEV1 (PD15) are given as 
geometric mean with 95% CI. Results are reported as ORcrude with 95% CI and ORadj with 95% CI and p-value. The associations are adjusted for age, smoking status (never 
smoker vs ever smoker), ICS treatment (low dose vs middle and high dose), and self-reported adherence with ICS (good/acceptable vs poor). aFractional exhaled nitric oxide. 
bLower limit of normal. cFor carbon monoxide.
Abbreviations: adj, adjusted; CI, confidence interval; OR, odds ratio; FVC, forced vital capacity; FEV1, forced expiratory volume in the first second; FENO, fractional exhaled 
nitric oxide; ICS, inhaled corticosteroids; LLN, lower limit of normal; NS, not significant.
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airway inflammation and by that may have prevented some 
exacerbations in our study.
Additionally, women with an asthma exacerbation during 
pregnancy were more likely to be nonatopic. This is in line 
with a study by Stenius-Aarniala et al,37 who found a higher 
rate of exacerbation and hospital admission in pregnant 
women with nonatopic asthma than atopic asthma.
There are several strengths and limitations in our study that 
need to be addressed. First of all, the study is the first of its kind 
to investigate the differences in asthma phenotypes in women 
with and without asthma exacerbation during pregnancy. We 
have used hypertonic saline-induced sputum to evaluate the 
airway inflammation in patients with asthma. This is a non-
invasive test, and the results correlate well with inflammation 
assessed by bronchoalveolar lavage (BAL).38 Furthermore, 
Simpson et al.31 have demonstrated that the inflammatory 
subtypes in sputum are stable over a longer term (5 years), 
and an important strength of our study is, therefore, that the 
examinations were performed within the first half year after 
birth and thereby may be likely to reflect the conditions prior 
to pregnancy. Additionally, Juniper et al16 have demonstrated, 
in a very limited cohort of 16 women, no changes in mean 
concentration of methacholine needed to produce a 20% fall 
in FEV
1
 from baseline (PC
20
) of methacholine inhalation test 
1 month postpartum compared to preconception mean. There 
are no such studies for mannitol challenge test.
Finally, there was no significant difference in spirom-
etry and level of F
E
NO measured during pregnancy and 
postpartum.
However, there are also some limitations. The study is 
limited by the fact that the tests are done postpartum and not 
during pregnancy. We found no significant association between 
asthma phenotype and the risk of asthma exacerbation during 
pregnancy, which may be explained by the modest number of 
subjects. In addition, sputum induction was possible in only 
80%, and failure of induction was associated with low F
E
NO. 
Women with neutrophilic airway inflammation not being able 
to produce sputum could explain the lack of a relationship; how-
ever, the average F
E
NO level in both groups was below 25 ppb.
The mannitol bronchial provocation test and induction 
of sputum with hypertonic saline were done on the same 
day. Nevertheless, Wood et al39 have demonstrated that 
mannitol bronchial provocation test does not enhance air-
way responsiveness, the quality of sputum cells collected, 
or the concentration of inflammatory mediators in sputum. 
A total of 104 women fulfilled the inclusion criteria and 
were invited to participate in the present study, of whom 50 
women agreed to participate. The examination procedures 
themselves took about 3 h and calculating the transport time 
and considering that they also have to bring a newborn with 
them it was expected that a high percentage would refuse to 
participate. Our cohort is representative of the entire MAP 
cohort; however, the results are not generalizable to the gen-
eral population of pregnant women with asthma due to the 
close monitoring of asthma during pregnancy.
Future studies are needed to investigate the link between 
asthma phenotypes and exacerbations during pregnancy by 
evaluating the airway inflammation early in pregnancy in a 
prospective design. Furthermore, there is need for studies 
investigating the stability of airway inflammatory charac-
teristics early in pregnancy and postpartum.
Conclusion
We found that women experiencing an asthma exacerbation 
during pregnancy are more responsive to mannitol and less 
likely to be atopic compared to women without an asthma 
exacerbation during pregnancy, whereas the present pilot 
study did not reveal a difference in inflammatory phenotype.
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